Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
- KOL Webinar Tomorrow, October 26, 2021 at 3:00 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company’s investigational RNA
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on October 26, 2021 , at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 30, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in adults with mixed dyslipidemia. ARO-APOC3 is the company’s investigational RNA
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 29, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Chardan's 5th Annual Genetic Medicines Conference – October 4-5, 2021 October 4, 2021 , 4:30 p.m.
View HTML
Toggle Summary Arrowhead Earns $10 Million Phase 1 Milestone Payment
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc. , (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 16th Annual BioPharma Virtual Conference – September 8-10, 2021 September 9, 2021 – Arrowhead management will
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
Conference Call and Webcast Today, August 5, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 5, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2021 . The company is hosting a conference call today,
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
- Full enrollment reached in Phase 2 SEQUOIA study of ARO-AAT PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for ARO-AAT,
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 14, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2021 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 14, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 42
View HTML